Big ideas
Bold leaders
Experts and bold leaders set to inspire at Longevity Summit Dublin
Meet the experts
The countdown to groundbreaking ideas starts now!
Don’t miss our early bird ticket sale! Offer ends March 10th
Don’t miss our early bird ticket sale! Offer ends March 10th
Big ideas
Bold leaders
Experts and bold leaders set to inspire at Longevity Summit Dublin
Meet the experts
The countdown to groundbreaking ideas starts now!
Professor of medicine, MD,PhD, MPH, FEFIM; specialist in internal medicine.
Longevity physician leading elite executives as longevity patients, integrating precision diagnostics of HLI, AI-based monitoring with deep aging analysis and individualized therapies towards healthy longevity, reversing the biological age and achieve optimal performance.
Clinician with over a decade of clinical practice experience in Switzerland, the USA and China
(Zurich/Basel, Boston/New York City, Shanghai)
Professor of medicine with a research focus on healthy longevity, geroncology, precision medicine.
Deeply passionate about next-generation medical technology, and the applications of AI for biomedical research and practice, digital health and innovative technology.
A Harvard- and Columbia-trained physician, author of over 80 peer-reviewed papers and a frequent speaker at scientific and medical conferences.
A demonstrated history of working in the medical practice industry on an international and cross-cultural level.
I am a scientist and entrepreneur with over 20 years of experience in academic research and the biotech industry. Currently, I serve as the CEO of Gero.ai, a cutting-edge biotechnology company focused on using AI to understand and combat aging and chronic diseases. We have developed proprietary physics-based machine learning models, known as Large Health Models (LHMs), to analyze human health data and predict health outcomes. These models distinguish the effects of aging from those of diseases, enabling more precise drug discovery and development. Our goal is to create therapies that not only treat age-related diseases but also potentially extend human healthspan and lifespan.
My scientific background lies at the intersection of physics and biology, with specific expertise in condensed matter physics, biophysics, and bioinformatics. I have conducted research at the Kurchatov Institute, University of Amsterdam, FOM institute AMOLF (NL), and the University of Innsbruck (Austria). I hold an M.S. in theoretical physics from the Moscow Institute of Physics and Technology and a Ph.D. from the University of Amsterdam. I have authored more than 80 publications with over 6000 citations (h-index of 37). My work has provided key contributions to the theoretical understanding of the aging process, the rate of aging, and the limits of lifespan and age reversion.
Associate Professor at National University of Singapore, YLL School of Medicine and Yale-NUS College (inaugural faculty) with a demonstrated history in leading independent biomedical research and higher education. Research interest in ageing, mitochondria, pharmacological interventions, biological ageing clocks and tools for modelling of mechanisms of ageing and disease.
Internationally recognized for my research in the basic biology of aging and as a visionary committed to translating research discoveries into new ways of delaying, detecting, preventing and treating human aging and associated diseases.
From 2010 to 2016 I was the President and CEO of the Buck Institute for Research on Aging. Continuing my passion for longevity, I’m currently the Director of the Centre for Healthy Longevity at the Yong Loo Lin School of Medicine at National University Singapore. I also serve as a Distinguished Professor in Biochemistry and Physiology. The Centre seeks to demonstrate that ageing interventions can be successfully employed in humans to extend healthspan, the disease-free and highly functional period of life. Other goals include world class preclinical research to better understand the biology of ageing and community-based approached to improve health quality with ageing in Singapore.
I have adjunct appointments at the Leonard Davis School of Gerontology at USC and the Department of Biochemistry at the University of Washington, where I served as a faculty member from 2001 to 2010.
In addition, I’m actively involved with a number of Biotechnology companies, serving in consulting and Board capacities, as is Scientific Director of Affirmative Health. Also serving as a Co-Editor-In-Chief at Aging Cell.
Finally, setting my footprint internationally I have been in China, where I was a Visiting Professor at the Aging Research Institute at Guangdong Medical College from 2009 to 2014.
As a cardiologist and health transformation coach, I have over 20 years of experience in helping people improve their health and wellbeing through lifestyle medicine and behaviour design. I am the CEO and owner of RK Cardiology Health Improvement Coaching, a hybrid service that provides personalised and evidence-based coaching programs for individuals and groups who want to achieve optimal health.
I am a board member of the European Lifestyle Medicine Organization (ELMO), a non-profit organization that promotes the advancement and dissemination of lifestyle medicine in Europe and beyond. I collaborate with other health professionals, researchers, and policymakers to advocate for the integration of lifestyle medicine into health systems and education. My mission is to inspire and empower people to make positive changes in their lives and to create a healthier and happier society.
Dr. Matt Kaeberlein is the Chief Executive Officer at Optispan, Inc., Affiliate Professor of Oral Health Sciences at the University of Washington, and Co-Director of the Dog Aging Project. Dr. Kaeberlein’s research interests are focused on understanding biological mechanisms of aging in order to facilitate translational interventions that promote healthspan and improve quality of life for people and companion animals. He is a Fellow of the American Association for the Advancement of Science (AAAS), the American Aging Association (AGE), and the Gerontological Society of America (GSA). Dr. Kaeberlein has published more than 250 scientific papers in the field of aging biology and has received several prestigious awards including young investigator awards from the Ellison Medical Foundation and the Alzheimer’s Association, the Vincent Cristofalo Rising Star in Aging Research Award, the Murdock Trust Award, the NIA Nathan W. Shock Award, and the Robert W. Kleemeier Award for outstanding research in the field of gerontology. Dr. Kaeberlein is the founding Director of the University of Washington Healthy Aging and Longevity Research Institute, former Director of the NIH Nathan Shock Center of Excellence in the Basic Biology of Aging and the Biological Mechanisms of Healthy Aging Training Program at the University of Washington, and former CEO and Chair of the American Aging Association.
Founder | Global Apheresis
He is a Harvard trained immunologist
He is an internationally recognized pioneer in the field of apheresis and has more than 100 publications on the subject.
He has served two terms on the Board of Directors of American Society For Apheresis and is currently a member of the Board of Directors of the International Society of Apheresis and is a member of the editorial board of the Journal of Transfusion and Apheresis Science.
He has received multiple awards for his contributions to the field of apheresis and has served as Chairman of the Division of Immunotherapy at California Pacific Medical Center. He was the founder and President of the Bay Area Mobile Apheresis Program and Senior Vice President and Medical Director for Apheresis for Fresenius Medical Care, NA.
Recently, DK founded Global Apheresis and co-founded Lyfspan, a company devoted to the research of aging. He is also a senior visiting scientist at the Buck Institute for the Research of Aging.
Dr. Kiprov pioneered the use of Therapeutic Plasma Exchange (TPE) in ameliorating the effects of aging and is conducting a number of controlled and uncontrolled studies. The early results are already published.
Founder & CEO | Accelerated Biosciences Corp
Yuta is the founder and CEO of Accelerated Bio, a regenerative medicine company based in Philadelphia commercializing the human Trophoblast Stem Cell (hTSC). hTSCs are the earliest pre-implantation, pre-placental cells that can be sourced ethically from an ectopic pregnancy. These naïve cells can scale to 85 population doublings with natural immune privilege, making them the most ideal starting cell source for allogeneic cell & gene therapies. The hTSC platform has been awarded 53 patents, providing freedom-to-operate for partners looking for a clear pathway to commercialization.
Yuta is passionate about accelerating cell & gene therapies to advance healthy longevity. Accelerated Bio’s pipeline includes Parkinson’s Disease, Type 1 Diabetes, as well as Cell Senescence for longevity.
Yuta has dual B.A. degrees in economics and legal studies from the University of California, Berkeley. Yuta earned his MBA in 2009 from China Europe International Business School (CEIBS) in Shanghai, China and graduated with the Outstanding Graduate of the Year Award.
Businessman, published author and current CEO of Longevity Events Limited, which hosts the annual Longevity Summit Dublin. I have lectured business strategy, mentored a number of organisations in strategic development and sit on a number of boards. My interests include accelerating technologies and their implications on healthcare and society at large.
Michael Ringel is a Managing Director and Senior Partner at BCG, and the former Global Leader of Research and Product Development/Innovation. His TED talk on innovation can be viewed at TED.com.
He is deeply involved in longevity, lifespan, and healthspan research, sitting on the Boards of Hevolution Foundation US and the American Federation for Aging Research. He is also Strategic Advisor for Life Biosciences, a biotechnology company focused on autophagy and partial reprogramming.
Prior to these roles, Michael worked in academia, pursuing research in theoretical population dynamics and conducting field experiments in the Amazon basin near Manaus, Brazil.
Michael has a B.A. summa cum laude in biology from Princeton University, a Ph.D. in biology from Imperial College and a J.D. cum laude from Harvard Law School.
I am Kenneth, a seasoned biotech investor, rejuvenation biohacker, and syndicate lead for AngelList’s Human Longevity and Rejuvenation Syndicate. With a deep understanding of age-related infirmities and the therapeutic landscape, I challenge conventional notions of lifespan and healthspan, envisioning a future where rejuvenation transforms our understanding of longevity. I co-founded and manage VivaSparkle’s syndicate, investing in promising biotech companies, and spearhead the Riley Farm Development project promoting sustainable real estate and nature conservation. With a background in software development and a track record of innovative solutions, I bring expertise and passion to the field of rejuvenation. My relentless pursuit of groundbreaking solutions stems from a firm belief that rejuvenation holds the potential to redefine the limits of human longevity.
Genomic Medicine | University of Cambridge
Cambridge University Genomic Medicine PhD on a mission to reshape the future of women’s health by developing prediction tools and next generation therapeutics for female reproductive disorders.
A young leader with an excellent international academic record (Nature, Science, Nature Medicine) and outstanding achievements in health-tech transfer and innovations. Based on her impact, Stasa was awarded ‘McKinsey&Company Next Generation Women Leader’ for 2020, the best young investigator under the age of 40 by the International Menopause Society (‘Robert Greenblatt Award’), one of ten best UK young scientists in the biomedical sector by the UK Government ‘STEM for Britain’, and she is considered as one of 11 scientists with the highest impact on innovations in women’s health and menopause by Forbes.
Professional figure skater and violinist.
Horse rider.
Judith is a venture capital investor specialising in the longevity sector, a biohacker with over 15 years of experience, and a serial entrepreneur turned VC. She is building longevity clinics in the Middle East and co-founded the Longevity Clinic Builder Network. Judith also co-organises Longevity Week Berlin, bringing together thought leaders in healthspan optimisation. As an advisor to family offices and senior allocators, she focuses on non-biotech longevity investments and shares her personal insights on extending health and lifespan. Her mission is to contribute one gigayear of healthy lifespan to humanity by acting as an enabler, multiplier, and advocate for meaningful, systemic change.
She is also the founder of Biohacking Eve, a platform centred on women’s health optimisation, with the goal of empowering women through education and biohacking insights.